Download presentation
Presentation is loading. Please wait.
Published byThorbjørn Sander Lund Modified over 5 years ago
1
The combination of trastuzumab and SU11274 abrogate Akt phosphorylation.
The combination of trastuzumab and SU11274 abrogate Akt phosphorylation. Serum-starved BT474 cells (A) and SKBR3 cells (B) were treated with 1 μmol/L SU11274 in the presence or absence of 21 μg/mL trastuzumab. Whole-cell lysates of BT474 and SKBR3 cells were collected after treatment and analyzed for phosphorylated Akt, phosphorylated Erk, and actin content by SDS-PAGE followed by Western blot. David L. Shattuck et al. Cancer Res 2008;68: ©2008 by American Association for Cancer Research
Similar presentations
© 2024 SlidePlayer.com. Inc.
All rights reserved.